跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 136 条关于
“Sequoia”
全部
136
临床试验
71
药物
2
机构
1
资讯
62
2年前
Aficamten Shows Long-Term Safety and Cardiac Benefits in HCM Patients
去年
SEQUOIA Trial Data Reveals Sustained Responses with Zanubrutinib in High-Risk CLL Patients
去年
Five-Year SEQUOIA Data Confirms Zanubrutinib's Long-Term Efficacy in High-Risk CLL/SLL Patients
去年
Novel Regimens Show Promise in CLL/SLL Treatment, Offering Durable Remissions and Improved Outcomes
去年
AI Tool Predicts Cancer Gene Signatures from Biopsy Images with High Accuracy
去年
Cytokinetics' Aficamten Advances in Regulatory Review for Obstructive Hypertrophic Cardiomyopathy
2年前
Zanubrutinib Combination Therapies Show Promise in High-Risk CLL/SLL Treatment
去年
BeiGene's BRUKINSA Receives European Commission Approval for CLL Treatment
去年
Zanubrutinib Shows Limited Cost-Effectiveness Against R-Bendamustine for First-Line CLL Treatment in China
去年
BeiGene's Brukinsa and Novel Assets Show Promise in CLL Treatment at ASH 2024
第 1 页,共 7 页
上一页
下一页